Company: EUDAW
Filing Date: 2025-12-04
Form Type: 424B5
Source: 0001493152-25-026224
Chunk: 13

Company: EUDA Health Holdings Ltd
Filing Date: 2025-12-04
Form: 424B5
Chunk 13
---
 EUDA will be required to further design, document and test the Company’s internal controls over financial reporting to comply with Sarbanes-Oxley Act Section 404. If existing material weaknesses or control deficiencies are not remediated or if material weaknesses or control deficiencies occur in the future, EUDA may be unable to report the Company’s financial results accurately on a timely basis or help prevent fraud, which could cause EUDA’s reported financial results to be materially misstated and result in the loss of investor confidence or delisting and cause the market price of EUDA’s ordinary shares to decline. If we have material weaknesses in the future, it could affect the financial results that the Company reports or create a perception that those financial results do not fairly state EUDA’s financial position or results of operations. Either of those events could have an adverse effect on the value of the Company’s ordinary shares.

Further, even if EUDA concludes that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP, because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company’s results of operations or cause EUDA to fail to meet future reporting obligations.

Risks Associated with this Offering

It is not likely that the Investor will pay us the Exercise Price to exercise the Warrant unless among other things, our ordinary shares will trade above $6.00 during the ninety (90) days from the day of issuance of the Warrant (the “Cash Exercise Period”).

At the exercise price of $6.00 per share (the “Exercise Price”), the Warrant is currently “out of the money.” Unless and until among other things, the trading price of our ordinary shares will exceed the Exercise Price during the Cash Exercise Period, it is not likely that the Investor will pay us the Exercise Price in cash to exercise the Warrant.

There is no assurance that the conditions required for a Forced Exercise can be met, and that we can require the Investor to pay us the Exercise Price in cash during the Cash Exercise Period.

The highest closing price of our ordinary shares over the past 52 weeks as of the date of this prospectus is $6.30. Since the closing of our Business Combination with 8i Acquisition 2 Corp. in November 2022, the closing price of our ordinary shares has never reached